Rx Product News (January 2018)

Pharmacy Times, January 2018 Oncology, Volume 84, Issue 1

Read about the new Rx Products featured in January.

Janssen and ViiV Healthcare

INDICATION: The FDA has approved Juluca, the first, complete single-pill, 2-drug regimen for the treatment of HIV-1 infection in certain adults living with the disease who are virologically suppressed. Juluca is an antiretroviral combination of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen).

DOSAGE: Tablets: 50 mg of dolutegravir and 25 mg of rilpivirine

FOR MORE INFORMATION: janssen.com, viivhealthcare.com

CALQUENCEMANUFACTURED BY: AstraZeneca

INDICATION: The FDA has granted accelerated approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

DOSAGE: Capsule: 100 mg

FOR MORE INFORMATION: astrazeneca-us.com

VRAYLARMANUFACTURED BY: Allergan

INDICATION: The FDA has approved the supplemental new drug application for cariprazine (Vraylar, Allergan) for the maintenance treatment of adults with schizophrenia.

DOSAGE: Capsules: 1.5 mg, 3 mg, 4.5 mg, and 6 mg

FOR MORE INFORMATION: allergan.com

FASENRAMANUFACTURED BY: AstraZeneca

INDICATION: The FDA has approved benralizumab (Fasenra, AstraZeneca) for the add-on maintenance treatment of patients with severe asthma 12 years and older and with an eosinophilic phenotype.

DOSAGE: Subcutaneous injection, via a prefilled syringe

FOR MORE INFORMATION: astrazeneca-us.com